The Battle trial for personalizing therapy for lung cancer identified targets of high interest in treatment of lung cancer and using an adaptive randomized trial utilized real time biomarker analyses to predict sensitivity or resistance to targeted agents [ 22].
The trial utilized a commercial web-based product via a proctoring company that provided live, online invigilation using remote video monitoring, keystroke biometrics, photo matching and system lockdown to transform any standard personal computer into a secure testing workstation.
Our trial utilized a non-invasive device, guided by real-time imaging and thermometry, demonstrating BBB opening with millimeter accuracy, and its successful closure within 24 h.
Each trial utilized a flea-naïve cat host, minimizing the possibility of cat-derived, immune-mediated rickettsial clearance in feeding fleas.
Given the challenges of random assignment in large complex public health interventions [ 54], the trial utilized a quasi-experimental design.
The trial utilized a two-week run-in phase for dose escalation in the higher dose groups.
The trial utilized a novel, accurate, and precise noninvasive imaging biomarker, the MRI-PDFF, for assessment of treatment response and was conducted by an experienced multidisciplinary team of investigators with special expertise in advanced MR assessment of NASH.
49 This trial utilized a randomized, crossover design and each patient received denosumab 60 mg subcutaneously every 6 months for 12 months and alendronate 70 mg orally every week for 12 months, one after the other.
Although this trial utilized a more conservative and better-tolerated dose titration protocol than FREEDOM-C or FREEDOM-M, it failed to meet the primary end point, with a +10 m placebo-corrected Hodges Lehmann between-treatment median difference in 6MWD at 16 weeks (P=0.089).
The RV144 human immunodefiency virus (HIV) vaccine efficacy trial utilized a regimen combining recombinant canarypox vector ALVAC-HIV (i.e. expressing HIV type 1 (HIV-1) Gag, Pro and membrane-linked gp120 (vCP1521)) with HIV clades B and E gp120 envelope (Env) glycoprotein (Rerks-Ngarm et al., 2009), and showed an estimated vaccine efficacy of 31.2% (Rerks-Ngarm et al., 2009).
To enable a comparison of an IV regimen of decitabine with the standard subcutaneous cytarabine regimen, the trial utilized an open-label study design.
